These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 28918995)

  • 1. Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies.
    Ransohoff JD; Kwong BY
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):834-851. PubMed ID: 28918995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous Complications of Targeted Melanoma Therapy.
    de Golian E; Kwong BY; Swetter SM; Pugliese SB
    Curr Treat Options Oncol; 2016 Nov; 17(11):57. PubMed ID: 27645330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
    Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
    J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.
    Howard SC; Trifilio S; Gregory TK; Baxter N; McBride A
    Ann Hematol; 2016 Mar; 95(4):563-73. PubMed ID: 26758269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.
    Grávalos C; Sanmartín O; Gúrpide A; España A; Majem M; Suh Oh HJ; Aragón I; Segura S; Beato C; Botella R
    Clin Transl Oncol; 2019 May; 21(5):556-571. PubMed ID: 30284232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunoproteasome as a therapeutic target for hematological malignancies.
    Miller Z; Lee W; Kim KB
    Curr Cancer Drug Targets; 2014; 14(6):537-48. PubMed ID: 25059201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
    Sethi TK; Basdag B; Bhatia N; Moslehi J; Reddy NM
    Curr Hematol Malig Rep; 2017 Jun; 12(3):257-267. PubMed ID: 28233150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors.
    Gnanendran SS; Turner LM; Miller JA; Hwang SJE; Miller AC
    Curr Treat Options Oncol; 2020 Mar; 21(4):29. PubMed ID: 32193712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
    Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular targeted therapy in lymphoid leukemias].
    Kojima K; Ando T; Kimura S
    Nihon Rinsho; 2014 Jun; 72(6):1094-8. PubMed ID: 25016810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer.
    Tang N; Ratner D
    Dermatol Surg; 2016 Jan; 42 Suppl 1():S40-8. PubMed ID: 26730973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted agents: management of dermatologic toxicities.
    Burtness B
    J Natl Compr Canc Netw; 2014 May; 12(5 Suppl):793-6. PubMed ID: 24853219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
    Matsuki E; Younes A
    Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management.
    Hwang SJ; Anforth R; Carlos G; Fernandez-Peñas P
    Actas Dermosifiliogr; 2017; 108(1):6-16. PubMed ID: 27642030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The spectrum of cutaneous toxicities related to novel genitourinary cancer therapies.
    Daher R; Ruplin A; Gupta S; Spiess PE; Kamat AM; Cigliola A; Tateo V; Mercinelli C; Grivas P; Necchi A
    Crit Rev Oncol Hematol; 2024 Aug; 200():104420. PubMed ID: 38906514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical review.
    Marchetti M
    Expert Rev Pharmacoecon Outcomes Res; 2017 Oct; 17(5):469-480. PubMed ID: 28796569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous manifestations of nontargeted and targeted chemotherapies.
    Shi VJ; Levy LL; Choi JN
    Semin Oncol; 2016 Jun; 43(3):419-25. PubMed ID: 27178698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Management of adverse effects of targeted therapy toxicities in oncology].
    Coquan E; Henri P; de Raucourt S; Lireux B; Lamy E; Delcambre C; Sevin E; Dutriaux C; Bouhier-Leporrier K; Gervais R; Joly F
    Rev Prat; 2012 Jan; 62(1):17-25. PubMed ID: 22335060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary Dysgammaglobulinemia in Children with Hematological Malignancies Treated with Targeted Therapies.
    Tragiannidis A; Groll AH
    Paediatr Drugs; 2021 Sep; 23(5):445-455. PubMed ID: 34292515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.
    Carneiro BA; Kaplan JB; Giles FJ
    Expert Rev Hematol; 2015 Aug; 8(4):457-79. PubMed ID: 25938861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.